UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
August 25, 2020

electroCore, Inc.

(Exact name of registrant as specified in its charter)

Delaware	**001-38538**	**20-3454976**
(State or other jurisdiction of incorporation or organization)	**(Commission File Number)**	**(I.R.S. Employer Identification Number)**

150 Allen Road, Suite 201
Basking Ridge, NJ 07920
(Address of principal executive offices and zip code)

(973) 290-0097
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share	ECOR	NASDAQ Global Select Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 7.01. Regulation FD Disclosure.

electroCore, Inc. (the "Company") has made available a corporate presentation relating to its business that it intends to use at upcoming conferences and otherwise. A copy of such presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K.

The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the slides is summary information that is intended to be considered in the context of more complete information included in the Company's filings with the SEC and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in the presentation, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing or submission of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the slide titled "Forward Looking Statement" in Exhibit 99.1 attached hereto.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933. The information contained in this Item 7.01 and in the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	**Description of Exhibit**
99.1	electroCore, Inc. Corporate Presentation dated August 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

electroCore, Inc.

August 25, 2020

/s/ Brian Posner
Brian Posner
Chief Financial Officer

electroCore™

A Commercial-Stage Bioelectronic Medicine Company

Nasdaq: ECOR

Corporate Presentation

August 2020

Forward Looking Statement

In addition to historical information, this presentation may contain forward-looking statements with respect to our business, capital resources, strategy and growth reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to a number of risks, uncertainties and assumptions, and you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements may be based upon current estimates and expectations about future events and financial and other trends. There is no guarantee that future results, performance or events reflected in the forward-looking statements will be achieved or occur. No person assumes responsibility for the accuracy and completeness of the forward-looking statements, and, except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those or our situation may change in the future.

Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our management's beliefs and assumptions only as of the date they are made and are only predictions that may be inaccurate. You should read the Risk Factors set forth in our reports filed from time to time with the Securities and Exchange Commission, which factors may cause our actual future results may be materially different from what we expect.

Additionally, in an effort to provide additional information management believes is a useful indicator of operating performance for the fiscal quarter ended June 30, 2020, this presentation contains a financial measure not determined by generally accepted accounting principles (GAAP): Adjusted EBITDA net loss. A reconciliation to the most directly comparable GAAP financial measure of Net Loss is available on the presentation slide entitled "Adjusted EBITDA Reconciliation." The rationale for management's use of non-GAAP information is included in Exhibit 99.1 to the Company's Form 8-K furnished with the SEC on August 13, 2020.

electroCore At-a-Glance

NASDAQx	ECOR
Headquarters:	Basking Ridge, NJ
Market cap:	~$90M (8/12/20)
Recent close:	$1.96 (8/12/20)
Cash & marketable securities (6/30/20):	$29.2 million*

* Pro-forma for $10.3 million raised subsequent to June 30

gammaCore

Sapphire™

Experienced Management Team

Dan Goldberger
Chief Executive Officer
35 years

Brian Posner
Chief Financial Officer
35 years

Peter Staats
Chief Medical Officer
33 years

RMS MEDICAL PRODUCTS · XTANT MEDICAL · synergy disc Synergy Disc Replacement, Inc. · SOUND SURGICAL TECHNOLOGIES LLC · CELLECTAR BIOSCIENCES · Alliqua BIOMEDICAL · JOHNS HOPKINS SCHOOL of MEDICINE · PREMIER PAIN CENTERS

Investment Summary

Platform Therapy	FDA cleared, proprietary, non-invasive vagus nerve stimulator (nVNS) positioned to unlock the broad potential of bioelectronic medicine FDA Emergency Use Authorization granted to explore utility of nVNS in known or suspected COVID-19 patients experiencing an exacerbation of asthma-related symptoms
Large Initial Market	Cluster headache and migraine estimated to affect more than 36 million[1] adults in the U.S.
Attractive Revenue Model	Recurring revenue business model
Strong IP Portfolio	Patent coverage extends through 2033

[1] American Migraine Foundation

gammaCore

Sapphire™

1st FDA-cleared non-invasive vagus nerve stimulator

- Fast acting, highly targeted, comfortable, easy to use hand-held option
- Cleared for the prevention and treatment of cluster headache and for the prevention of migraine and treatment of acute migraine
- FDA EUA granted to explore potential benefits of gammaCore Sapphire CV in known or suspected COVID-19 patients
- Use alongside existing treatments; no drug-drug interactions or drug-like side effects
- Can use multiple times per day or month
- May reduce medication use leading to lower costs to treat cluster headache (UK's NICE)

nVNS and the Benefits of gammaCore

Benefits of nVNS

- The vagus nerve affects multiple organs and systems
- Activates multiple mechanisms of action
- Evidence supports possible future treatment for many indications
- Self-treating and no off-target effects
- Complementary to existing care

Unmet Need in Migraine & Cluster Headache

MIGRAINE

36 million U.S. adults[1]

Triptans represent 80% of prescribed acute therapies

40% of patients are dissatisfied or unresponsive to triptans[2]

More than half of insured migraineurs receive no Rx treatment[2]

gammaCore is FDA-cleared for migraine prevention and treatment of acute migraine

CLUSTER HEADACHE

400,000 U.S. patients[3]

Up to eight 15-180 min attacks per day

Considered one of the most painful conditions known; a "suicide headache"

gammaCore is FDA-cleared for the prevention of all types of cluster headache and for the acute treatment of episodic cluster headache

1. American Migraine Foundation
2. IMS Pharmetrics Plus.
3. Cephalalgia. 2008 Jun;28(6):614-8. doi: 10.1111/j.1468-2982.2008.01592.x. Epub 2008 Apr 16.

Growth in gammaCore Prescribers[1]



[1] Represents U.S. headache prescribers who have written at least one prescription

Headache Reimbursement Pathway

Aligned to stakeholder experience

PHYSICIANS
Write a prescription for use at home

PATIENTS
Acquire gammaCore from a specialty pharmacy with simple refill process

PAYERS
Manage utilization through pharmacy or medical benefit reimbursement

Commercial Payer Response

CURRENT PAYER COVERAGE

CVS Caremark, Express Scripts, Highmark Blue Cross Blue Shield, North Dakota Blue Cross Blue Shield, Federal Supply Schedule (VA, DoD, Indian Health Service), cash pay

PAYER ENGAGEMENT

Active discussions and negotiations with multiple national plans

REIMBURSEMENT PATH

Prescription model with periodic refill; can be reimbursed as pharmacy or medical benefit

Commercial Headache Reimbursement through PBMs

CVS/Caremark

gammaCore is reimbursed by CVS/Caremark at a non-exclusionary co-pay of roughly $50 - $75/month for those beneficiaries who have a benefit design that does not differentiate between drugs and devices

Approximately five million CVS/Caremark members currently have a benefit design of this type

Express Scripts (ESI)

gammaCore is reimbursed by ESI on all National Standard Formularies at a preferred copay of roughly $25 - $45/month for those beneficiaries who have a benefit design that does not differentiate between drugs and devices

Active Channels With Revenue Growth Opportunities

Driving Department of Defense sales through the Department of Veterans Affairs and Military Treatment Facilities

Growth in the UK by leveraging: 1) Innovation Technology Program Award for cluster headache, and 2) support from the National Institute for Health and Care Excellence (NICE) for the treatment of cluster headache

Paid Months Of Therapy By Quarter

Market Channel

■ US Commercial ■ VA/DOD ■ OUS

July paid months of therapy:

VA/Dod – 435 (vs. Q2 monthly avg of 329)

OUS – 368 (vs. Q2 monthly avg of 313)

Data through 6/30/20

Federal Supply Schedule Opportunity

An efficient call point for direct sales

>10 million
covered lives between the Veterans Admin., active military facilities and the Indian Health Service

~400,000 patients
saw VA healthcare providers for headache in 2018[1]

Migraine grew 10-fold
in the VA between 2004-2012[2]

Survey of 77k
active duty, reserve and National Guard members found that 7% of men and 21% of women had provider-diagnosed migraine[3]

VA | U.S. Department of Veterans Affairs

[1] Grinberg et al. Understanding the Prevalence and Geographic Distribution of Headache Disorders within the Veterans Health Administration. Poster presentation, AHS 2019
[2] Altalib et al. Increase in migraine diagnoses and guideline-concordant treatment in veterans, 2004-2012 Cephalalgia 2017;37:3-10
[3] Jankosky et al. Headache disorders in the millennium cohort: epidemiology and relations with combat deployment. Headache 2011;51:1098-1111

gammaCore – Platform Technology with Vast Potential

gammaCore is the only FDA cleared non-invasive VNS therapy

NEUROLOGY / PAIN

- **Cluster Headache[1]**
- **Migraine[1]**
- Post-traumatic headache
- Post-traumatic stress disorder
- Traumatic Brain Injury
- Subarachnoid hemorrhage[2]
- Stroke[2]



INFLAMMATION

- Reactive Airway Disease[2]
- Asthma exacerbations in known or suspected COVID-19 patients[3]
- Rheumatoid Arthritis
- Sjogren's Syndrome[2]

GASTROENTEROLOGY

Gastroparesis Ulcerative colitis Post-operative Ileus

[1] Cleared indications

[2] Independent Investigator initiated studies ongoing

[3] Cleared through FDA Emergency Use Authorization

Strong Rationale as a Potential COVID-19 Treatment

Testing the hypothesis that nVNS can improve the condition of COVID-19 patients

- **Emergency Use Authorization (EUA)** issued by FDA to facilitate the study and clinical use of gammaCore Sapphire™ CV (nVNS) for the acute treatment of asthma exacerbations in known or suspected COVID-19 patients
- Prior pilot studies have been successfully completed in other respiratory indications, including asthma, bronchoconstriction, exercise-induced bronchospasm, and COPD
- CE Mark approved in certain respiratory indications, including for the treatment or prevention of symptoms of reactive airway disease, which includes asthma, bronchoconstriction, exercise induced bronchospasm, and COPD in adults
- A paper, entitled, "Use of Non-Invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated with COVID-19: A Theoretical Hypothesis and Early Clinical Experience," has been published in the journal *Neuromodulation: Technology at the Neural Interface*

COVID-19 Investigator Initiated Trials (IITs)

Multiple ongoing IITs are assessing the potential utility of nVNS in COVID-19 respiratory symptoms

SAVIOR-1

Study Assessing Vagus Nerve Stimulation in COVID-19 Respiratory Symptoms

Lead investigator: Dr. Carlos Tornero

Hospital Clínico Universitario de Valencia, Valencia, Spain

Planned enrollment: 90 hospitalized patients with a confirmed diagnosis of or suspected/presumed to be COVID-19 positive

Study is assessing the reduced need for mechanical ventilation

Status: Currently enrolling

Hospital Clínic Universitari de València

SAVIOR-2

Lead investigator: Dr. Tariq Cheema

Allegheny General Hospital, Pittsburgh

Planned enrollment: 60 hospitalized patients with a confirmed diagnosis of or suspected/presumed to be COVID-19 positive

Study is assessing symptomatic and COVID-19 (or symptomatic and cytokine) specific endpoints

Status: Currently enrolling

AHN

H2 2020 & 2021 Anticipated Milestones*



* Based on current operating plan

Broad Intellectual Property Portfolio

electroCore owns all intellectual property on which the technology relies

Expansive pioneering IP coverage of non-invasive, transdermal neuro-stimulation in the neck

We have patent coverage extending out through 2033:

- High-frequency burst signals capable of passing comfortably through the skin
- Low-pass signal filtration that reduces signal harmonics that cause pain

>165

PATENTS AND PATENT APPLICATONS

~100 issued U.S. patents

>25 U.S. patent applications

>40 International patents

Summary Financials

$ In thousands	4Q 2018	1Q 2019	2Q 2019	3Q 2019	4Q 2019	1Q 2020	2Q 2020
GAAP revenue	368	410	623	683	675	734	753
Research and Development	3,460	3,460	2,510	2,275	1,623	1,523	1,031
SG&A	12,397	11,000	9,388	8,143	7,267	6,561	5,273
Operating loss	(15,681)	(14,211)	(12,380)	(10,894)	(8,606)	(8,013)	(5,923)
GAAP net loss	(15,335)	(13,862)	(12,101)	(10,688)	(8,498)	(7,959)	(4,742)
Adjusted EBITDAnet loss	(14,514)	(13,441)	(10,775)	(8,448)	(6,662)	(6,410)	(4,322)
Operating cash burn	**$11,900**	**$16,200**	**$11,200**	**$7,600**	**$9,400**	**$8,400**	**$5,200**

Q3 2020 preliminary guidance:

Revenue > $753,000

Cash burn < $4.5 million

Cash and marketable securities*	$29,200
Shareholders' equity	$21,543

*Pro-forma as of June 30, 2020.

Please see reconciliation of GAAP net loss to adjusted EBITDA net loss on slide 21

Adjusted EBITDA Reconciliation

	1Q 2019	2Q 2019	3Q 2019	4Q 2019	1Q 2020	2Q 2020
	($ in thousands)					
GAAP net loss	$ (13,862)	$ (12,101)	$ (10,688)	$ (8,498)	$ (7,959)	$ (4,742)
Provision for (benefit from) income taxes	-	-	-	$ 18	$ -	$ (1,171)
Depreciation and amortization	$ 26	$ 28	$ 99	$ 97	$ 97	$ 97
Stock-based compensation	$ 744	$ 727	$ 1,220	$ 1,205	$ 745	$ 1,003
Restructuring and other severance related charges	-	$ 850	$ 805	$ -	$ 365	$ 100
Legal fees associated with stockholders' litigation	-	-	$ 322	$ 641	$ 396	$ 402
Total other (income)/expense	$ (349)	$ (279)	$ (206)	$ (125)	$ (54)	$ (11)
Adjusted EBIDTA net loss	**$ (13,441)**	**$ (10,775)**	**$ (8,448)**	**$ (6,662)**	**$ (6,410)**	**$ (4,322)**

Capitalization Table

Fully diluted as of June 30, 2020

Common shares**	38,815,145	
Warrants	715,199	Exercise prices ranging from $5.68 to $12.60; expirations from April 1, 2021 through August 31, 2022
Options	4,606,407	Weighted average exercise price=$7.10, options generally vest over 4-year period (first options granted June 21, 2018)
Restricted Stock Units	1,376,545	RSUs which vest through April 2023.
Total	**45,513,296**	

As of April 14, 2020, 63% of ECOR shares outstanding are owned by retail investors and non-filers

** As of August 10, 2020 total shares outstanding are 44,525,853, reflecting shares issued subsequent to June 30, 2020.

Investment Summary

Platform Therapy	FDA cleared, proprietary, non-invasive vagus nerve stimulator (nVNS) positioned to unlock the broad potential of bioelectronic medicine FDA Emergency Use Authorization granted to explore utility of nVNS in known or suspected COVID-19 patients experiencing an exacerbation of asthma-related symptoms
Large Initial Market	Cluster headache and migraine estimated to affect more than 36 million[1] adults in the U.S.
Attractive Revenue Model	Recurring revenue business model
Strong IP Portfolio	Patent coverage extends through 2033

[1] American Migraine Foundation

APPENDIX

Acute Cluster Headache: ACT 1 & ACT 2

Pooled analysis of Episodic Cluster Headache from ACT 1 & ACT 2 Trials



Citation: de Coo IF, Marin JCA, Silberstein SD, et al. Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: a meta-analysis. *Cephalalgia*. 2019;39(8):967-977.

Acute Migraine: PRESTO Trial

Pain Freedom



Percent Pain Relief



gammaCore (n = 120) Control (n = 123)

Citation: Tassorelli C, Grazzi L, de Tommaso M, et al. Non-invasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology2018;91(4):e364-e373.

Cluster Headache Prevention: PREVA Trial

Reduction in Number of Attacks per Week



Percentage of Patients w/≥ 50% Reduction in Attack Frequency



Adjunctive gammaCore Standard of care

mITT - Patients who provided data in the randomized period sufficient to compare to baseline measurements

Citation: Non-invasive Vagus Nerve Stimulation for PREVention and Acute Treatment of Chronic Cluster Headache (PREVA): A Randomised Controlled Study. Gaul C, Magis D, Diener H, Silver N, Magis D, Reuter U, Andersson A, Liebler E, Straube A, PREVA Study Group. Cephalagia. 2016 May; 36(6):534-46. doi: 10.1177/0333102415607070

Indication and Important Safety Information

gammaCore SapphireTM (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck.
gammaCore is indicated for:

- The preventive treatment of migraine headache in adult patients.
- The acute treatment of pain associated with migraine headache in adult patients.
- Adjunctive use for the preventive treatment of cluster headache in adult patients.
- The acute treatment of pain associated with episodic cluster headache in adult patients.

The safety and effectiveness of gammaCore (nVNS) have not been established in the acute treatment of chronic cluster headache

The long-term effects of the chronic use of gammaCore have not been evaluated

Safety and efficacy of gammaCore have not been evaluated in the following patients, and therefore gammaCore is NOT indicated for:

- Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
- Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
- Pediatric patients
- Pregnant women
- Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Patients should not use gammaCore if they:

- Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
- Have a metallic device such as a stent, bone plate, or bone screw implanted at or near their neck
- Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

In the US, the FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders, such as acute respiratory stress disorder associated with COVID-19.

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product: www.gammacore.com

Please also see the instructions for Use for gammaCore CV for all of the important warnings and precautions specific to gammaCore CV and its use pursuant to the Emergency Use Authorization (EUA): https://www.fda.gov/media/139970/download